Valuation & Deal Economics
What is the asset worth, and what will a partner actually pay?
The Problem We Solve
Most valuations stop at a number. Ours don't, because the number only matters if it tells you what to fund, when to partner, and what terms to hold out for.
We build probability-adjusted valuations rigorous enough to defend to a board, an investor, or the other side of the table, and we carry them the step most advisors won't: translating value into the specific economics of a deal.
Deliverables:
Probability-adjusted asset valuation
Bottom-up, scenario-based revenue forecast
Deal-term benchmarks (upfront, milestones, royalties)
Unredacted transaction database access
Scenario and sensitivity analysis
Timing and value step-up modeling
Board- and investor-ready materials
Fully transparent model and assumptions
How it works
Step 1
Build the Valuation
We build probability-adjusted valuations from a bottom-up, scenario-based revenue forecast, not a single point estimate, but the range of outcomes that could actually happen.
Step 2
Benchmark the Deal Terms
We benchmark deal terms against a proprietary database of confidential, unredacted transaction terms, so your expectations rest on what deals actually contain, not on the redacted figures disclosed publicly.
Step 3
Model the Timing
We model the economics of timing: the step-up in value from the next readout weighed against the cost and risk of waiting for it.
YOUR EDGE
Strategic Use Cases
You need an independent, defensible valuation of an asset, or the whole company, for a board decision, a financing, or a fairness view.
You're heading into partnering discussions and need to know what terms the asset can actually command.
You're weighing whether to license now or advance the asset further before partnering.
You need to understand how an upcoming clinical or regulatory event will move value, before it happens, not after.
WHO THIS IS FOR
The Deal-Terms Database
We derive market-value deal terms from a proprietary database of confidential, unredacted transaction terms: the actual economics of real deals, not the redacted figures disclosed publicly. Few advisors can benchmark terms against what deals truly contain. We can.
